Dear Author, Here are the proofs of your article. • You can submit your corrections online, via e-mail or by fax. • For online submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers. • You can also insert your corrections in the proof PDF and email the annotated PDF. • For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page. • Remember to note the journal title, article number, and your name when sending your response via e-mail or fax. • Check the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown. • Check the questions that may have arisen during copy editing and insert your answers/ corrections. • Check that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the Edited manuscript. • The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct. • Please do not make changes that involve only matters of style. We have generally introduced forms that follow the journal’s style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof. • If we do not receive your corrections within 48 hours, we will send you a reminder. • Your article will be published Online First approximately one week after receipt of your corrected proofs. This is the official first publication citable with the DOI. Further changes are, therefore, not possible. • The printed version will follow in a forthcoming issue. Please note After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: http://dx.doi.org/[DOI]. If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: http://www.link.springer.com. Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.
21
Embed
Electrostatic effects control the stability and iron release kinetics of ovotransferrin
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Dear Author,
Here are the proofs of your article.
• You can submit your corrections online, via e-mail or by fax.
• For online submission please insert your corrections in the online correction form. Alwaysindicate the line number to which the correction refers.
• You can also insert your corrections in the proof PDF and email the annotated PDF.
• For fax submission, please ensure that your corrections are clearly legible. Use a fine blackpen and write the correction in the margin, not too close to the edge of the page.
• Remember to note the journal title, article number, and your name when sending yourresponse via e-mail or fax.
• Check the metadata sheet to make sure that the header information, especially author namesand the corresponding affiliations are correctly shown.
• Check the questions that may have arisen during copy editing and insert your answers/corrections.
• Check that the text is complete and that all figures, tables and their legends are included. Alsocheck the accuracy of special characters, equations, and electronic supplementary material ifapplicable. If necessary refer to the Edited manuscript.
• The publication of inaccurate data such as dosages and units can have serious consequences.Please take particular care that all such details are correct.
• Please do not make changes that involve only matters of style. We have generally introducedforms that follow the journal’s style.Substantial changes in content, e.g., new results, corrected values, title and authorship are notallowed without the approval of the responsible editor. In such a case, please contact theEditorial Office and return his/her consent together with the proof.
• If we do not receive your corrections within 48 hours, we will send you a reminder.
• Your article will be published Online First approximately one week after receipt of yourcorrected proofs. This is the official first publication citable with the DOI. Further changesare, therefore, not possible.
• The printed version will follow in a forthcoming issue.
Please note
After online publication, subscribers (personal/institutional) to this journal will have access to thecomplete article via the DOI using the URL: http://dx.doi.org/[DOI].If you would like to know when your article has been published online, take advantage of our freealert service. For registration and further information go to: http://www.link.springer.com.
Due to the electronic nature of the procedure, the manuscript and the original figures will only bereturned to you on special request. When you return your corrections, please inform us if you wouldlike to have these documents returned.
Organization Institute of Microbial Technology, Council of Scientific and IndustrialResearch
Address Sector 39A, Chandigarh, India
Email
Author Family Name KumarParticle
Given Name RajeshSuffix
Division School of Chemistry and Biochemistry
Organization Thapar University
Address Patiala, 147004, India
Email
Schedule
Received 4 August 2013
Revised
Accepted 29 April 2014
Abstract The contribution of electrostatic interactions to the stability of ovotransferrin-Fe3+ (oTf-Fe3+) complex hasbeen assessed by equilibrium experiments that measure iron retention level of diferric-ovotransferrin(Fe2oTf) as a function of pH and urea in the presence of salts (NaCl, Na2SO4, NaBr, NaNO3) and sucrose at25 °C. As [salt] is increased, the pH-midpoint for iron release increases monoexponentially and plateau at~0.4(±0.05) M NaCl/NaBr/NaNO3 or ~0.15(±0.03) M Na2SO4. However, at pH 7.4, the urea-midpoints foriron release (based on fluorescence emission at 340 nm) and for unfolding of Fe2oTf and apo-ovotransferrin(based on ellipticity values at 222 and 282 nm) decrease at low salt concentrations [≤0.1(±0.02) M Na2SO4
or ≤0.35(±0.15) M NaCl], but increase at higher salt concentrations. Furthermore, Na2SO4 has a greater effectthan NaCl in increasing the urea-midpoints for iron release and unfolding. These results indicate that at lowsalt concentrations, the electrostatic effects destabilize the oTf-Fe3+ complex and also decrease the structuralstability of the proteins. In contrast, at higher concentrations, salt ions behave according to Hofmeister series.At pH 5.6, as [salt] is increased, the rate constants for reductive iron release (Fe2+ release) and ureadenaturation-induced iron release (Fe3+ release) from the N-lobe of oTf (FeNoTf) increase monoexponentiallyand plateau at ~0.4(±0.1) M NaNO3/NaCl or ~0.2(±0.05) M Na2SO4. These results suggest that the anion-binding-induced conformational change as well as the electrostatic screening of surface Coulombicinteractions plays important role in accelerating the iron release from FeNoTf under endosomal pH conditions.
Keywords (separated by '-') Iron release - Electrostatic interactions - Anion-binding - Conformational change - Structural stability
Footnote Information Electronic supplementary material The online version of this article (doi:10.1007/s00775-014-1145-2)contains supplementary material, which is available to authorized users.
Metadata of the article that will be visualized in OnlineAlone
Electronic supplementarymaterial
Below is the link to the electronic supplementary material.MOESM1: Supplementary material 1 (PDF 57 kb).
UNCORRECTEDPROOF
ORIGINAL PAPER1
2 Electrostatic effects control the stability and iron release kinetics
3 of ovotransferrin
4 Sandeep Kumar • Deepak Sharma •
5 Rajesh Kumar • Rajesh Kumar
6 Received: 4 August 2013 /Accepted: 29 April 20147 � SBIC 2014
8 Abstract The contribution of electrostatic interactions to
9 the stability of ovotransferrin-Fe3? (oTf-Fe3?) complex
10 has been assessed by equilibrium experiments that measure
11 iron retention level of diferric-ovotransferrin (Fe2oTf) as a
12 function of pH and urea in the presence of salts (NaCl,
13 Na2SO4, NaBr, NaNO3) and sucrose at 25 �C. As [salt] is
14 increased, the pH-midpoint for iron release increases mo-
15 noexponentially and plateau at *0.4(±0.05) M NaCl/
16 NaBr/NaNO3 or *0.15(±0.03) M Na2SO4. However, at
17 pH 7.4, the urea-midpoints for iron release (based on
18 fluorescence emission at 340 nm) and for unfolding of
19 Fe2oTf and apo-ovotransferrin (based on ellipticity values
20 at 222 and 282 nm) decrease at low salt concentrations
21 [B0.1(±0.02) M Na2SO4 or B0.35(±0.15) M NaCl], but
22 increase at higher salt concentrations. Furthermore, Na2-23 SO4 has a greater effect than NaCl in increasing the urea-
24 midpoints for iron release and unfolding. These results
25 indicate that at low salt concentrations, the electrostatic
26 effects destabilize the oTf-Fe3? complex and also decrease
27 the structural stability of the proteins. In contrast, at higher
28 concentrations, salt ions behave according to Hofmeister
29 series. At pH 5.6, as [salt] is increased, the rate constants
30 for reductive iron release (Fe2? release) and urea dena-
31 turation-induced iron release (Fe3? release) from the
32N-lobe of oTf (FeNoTf) increase monoexponentially and
33plateau at*0.4(±0.1) M NaNO3/NaCl or*0.2(±0.05) M
34Na2SO4. These results suggest that the anion-binding-
35induced conformational change as well as the electrostatic
36screening of surface Coulombic interactions plays impor-
37tant role in accelerating the iron release from FeNoTf under
38endosomal pH conditions. 39
40Keywords Iron release � Electrostatic interactions �
44The stability of proteins is generally governed by nonco-
45valent interactions such as hydrophobic [1, 2], electrostatic
46[3–7], and hydrogen bonding [8, 9]. However, the relative
47contributions of these interactions to protein stability are
48not fully resolved. In particular, the role of ionic interac-
49tions in protein stability is relatively more complex [10].
50Buffer conditions such as pH and salt can have dramatic
51effect on the stability and biological functions of proteins.
52For example, the low pH triggers a large conformational
53change in transferrins (Tfs), which is a critical step for iron
54release in endosome [11–25]. In general, pH modulates the
55protein stability by altering the charges on ionizable groups
56in the proteins through protonation or deprotonation [26].
57Salt ions also modulate the stability of proteins [27, 28]. At
58low concentrations, salt ions affect the stability of proteins
59by altering the electrostatic (Debye-Huckel) screening of
60Coulombic interactions [9, 29, 30]. At relatively higher
61concentrations, salt ions follow the Hofmeister effect,
62which eventually depends on the nature of added ions and
63modulates the stability of proteins by increasing the surface
A1 Electronic supplementary material The online version of thisA2 article (doi:10.1007/s00775-014-1145-2) contains supplementaryA3 material, which is available to authorized users.
A4 S. Kumar � R. Kumar � R. Kumar (&)
A5 School of Chemistry and Biochemistry, Thapar University,
758 and Fe3? release from FeNoTf are due to the interference
759 with hydrophobic interactions, then kosmotropic salt (i.e.,
760 increase the macromolecular stability by strengthening the
761 hydrophobic interactions [31, 32, 34]) such as Na2SO4
762 should slow down the Fe2? and Fe3? release from FeNoTf
763 via strengthening the intramolecular hydrophobic interac-
764 tions. But, within the pH range of 7.4–5.6, the current
765 results reveal that at low salt concentrations
766 [B0.12(±0.05) M NaCl/NaNO3 or Na2SO4 (pH 7.4);
767 B0.4(±0.1) M NaNO3/NaCl or 0.2(±0.05) M Na2SO4 (pH
768 5.6)], all the salts examined (NaCl, NaNO3, and Na2SO4)
769 here promote Fe2? and Fe3? release from FeNoTf. The
770 current results also reveal that at higher salt concentrations
771 [C0.12(±0.05) M NaCl/NaNO3 or Na2SO4], the salt ions
772 retard the Fe2? and Fe3? release from FeNoTf at pH 7.4
773 (Figs. 7c, 9c), while they accelerate the Fe2? and Fe3?
774 release at pH 5.6 (Figs. 7d, 9d). At low to intermediate
775 concentrations (0.01–0.35 M), the effects of salt on protein
776 stability are generally attributed to ionic screening effect
777 [9, 29, 30]. On the other hand, the specific ion binding
778 effect of salt is generally apparent at millimolar concen-
779 trations [108] while hydrophobic effect occurs at molar
780 concentrations ([0.5 M) [4, 5, 9, 29, 30, 107]. In dilute to
781 moderately concentrated ionic solution, an extended
782 Debye-Huckel model can easily interpret the effect of ionic
783 strength on the rate of iron release from human serum
784 diferric transferrin [30]. At pH 5.6, the log kobs for Fe2?
785 and Fe3? release increases linearly with I1/2/(1 ? I
1/2)
786 (Insets of Figs. 7d and 9d), indicating that the Debye-
787 Huckel screening of diffusive counterions accelerates the
788 iron release from FeNoTf under endosomal pH conditions.
789 Finally, the opposite effects of salts and sucrose (i.e., salt
790 prompts iron release while sucrose inhibits it) confirm that
791 the acceleration of the iron release by salt is not due to the
792 hydrophobic effect.
793Both anion binding to KISAB sites and electrostatic
794screening effect of electrolytes control the kinetics
795of iron release from FeNoTf
796To emphasize the allosteric effect on iron release, Egan
797et al. [76, 77, 82, 86] proposed naming the sites to which
798nonsynergistic anions bind as ‘‘kinetically significant
799anion binding’’ or KISAB sites. It is widely accepted that
800the anions binding to KISAB sites influence the rate of
801iron release from Tfs [109, and references therein].
802However, the KISAB sites have not been well character-
803ized [109]. Few earlier studies have shown that multiple
804KISAB sites exist for each lobe of Tf [15, 17, 22, 72, 74,
80583, 109]. A recent report shows that Arg143 serves as an
806authentic KISAB site in the N-lobe of human sTf [74].
807While both electrostatic effect (Debye-Huckel screening
808of diffusive counterions) and anions binding to the KISAB
809sites influence the rates of iron release from FeNoTf, the
810extent of these two effects on rates of iron release will
811depend on the pH of reaction medium and the concen-
812tration of anions. The N-lobe is the first lobe to release
813iron [62], so it is to be noted that the concentration of
814anion has the greatest effect on iron release from the
815N-lobe [74]. At low salt concentrations and at pH 7.4,
816Debye-Huckel screening of diffusive counterions facili-
817tates the iron release from FeNoTf but under these con-
818ditions of pH and salt, anions binding to KISAB sites may
819have little effect on iron release because at neutral pH
820only weak interactions exist between the anions and KI-
821SAB sites [72]. At mildly acidic pH (pH *5.6), the
822anions’ binding strength to KISAB sites increases [72],
823which results in acceleration of iron release from N-lobe
824of Tfs [72]. The previous section has presented several
825lines of evidence which suggests that at pH 5.6, Debye-
826Huckel screening of diffusive counterions facilitates iron
827release from FeNoTf. So, at pH *5.6, it is likely that both
828anions binding to the KISAB sites and ionic screening of
829electrostatic interactions together facilitate the iron release
830from FeNoTf.
831Conclusions
832To assess the effects of salts and sucrose on the stabiliza-
833tion of oTf-Fe3? complex and structural stability of Fe2oTf,
834we have studied the Fe2oTf as a function of pH and urea in
835the presence salt (NaCl, Na2SO4, NaBr, and NaNO3) and
836sucrose. Interestingly, the low concentrations of salt
837destabilize the oTf-Fe3? complex and also decrease the
838structural stability of Fe2oTf. In contrast, the higher con-
839centrations of salt stabilize the oTf-Fe3? complex and also
840increase the structural stability of Fe2oTf. The current
841study reveals that the destabilization of Fe2oTf by salt
J Biol Inorg Chem
123Journal : Large 775 Dispatch : 12-5-2014 Pages : 16
Article No. : 1145h LE h TYPESET
MS Code : JBIC-13-08-00139 h CP h DISK4 4
Au
tho
r P
ro
of
UNCORRECTEDPROOF
842 results from both destabilization of oTf-Fe3? complex and
843 ionic screening of electrostatic interactions. At pH 7.4, the
844 low concentrations of salt (NaCl, NaNO3, and Na2SO4)
845 promote the Fe2? and Fe3? release from FeNoTf. At higher
846 concentrations, these salts inhibit the Fe2? and Fe3? release
847 and salt ions behave according to Hofmeister series. At pH
848 5.6, these salts also accelerate the Fe2? and Fe3? release
849 from FeNoTf. However, at pH 5.6, the salt-induced accel-
850 eration of Fe2? and Fe3? release is particularly pronounced
851 at low salt concentrations but is saturated at
852 *0.2(±0.05) M Na2SO4 or *0.4(±0.1) M NaNO3/NaCl,
853 which suggests that the Coulombic interactions play crucial
854 role in the accelerating the iron release from FeNoTf under
855 endosomal pH conditions. The current results also suggest
856 that there is a general effect from Debeye-Huckel screening
857 that operates in addition to the anion binding to KISAB or
858 any unrecognized sites in regulating the kinetics of iron
859 release from FeNoTf at pH *5.6.
860 Acknowledgments This work was supported by DST-SERC Fast861 Track Research Grant (to R.K., project No. SR/FT/CS-070/2009), a862 Ramalingaswami Re-entry Fellowship by DBT, India (to D.S., BT/863 RLF/RE-ENTRY-33-2010), and UGC major grant (to R.K., F. No.864 41-258/2012 (SR), Government of India.
865
866 References
867 1. Jaenicke R, Bohm G (1998) Curr Opin Struct Biol 8:738–748868 2. Pace CN (1995) Methods Enzymol 259:538–554869 3. Karshikoff A, Ladenstein R (2007) In: Uversky VN, Permyakov870 E (eds) Nova Biomedical Books, New York871 4. Perl D, Holtermann G, Schmid FX (2001) Biochemistry872 40:15501–15511873 5. Jayaraman S, Gantz DL, Gursky O (2006) Biochemistry874 45:4620–4628875 6. Benjwal S, Jayaraman S, Gursky O (2005) Biochemistry876 44:10218–10226877 7. Dominy BN, Perl D, Schmid FX, Brooks CL 3rd (2002) J Mol878 Biol 319:541–554879 8. Vogt G, Woell S, Argos P (1997) J Mol Biol 269:631–643880 9. Elcock AH, McCammon JA (1998) J Mol Biol 280:731–748881 10. Kohn WD, Kay CM, Hodges RS (1997) J Mol Biol882 267:1039–1052883 11. Lee DA, Goodfellow JM (1998) Biophys J 85:2747–2759884 12. Rinaldo D, Field MJ (2003) Biophys J 85:3485–3501885 13. Bobst CE, Zhang M, Kaltashov IA (2009) J Mol Biol886 388:954–967887 14. Aisen P, Listowsky I (1980) Annu Rev Biochem 49:357–393888 15. Dewan JC, Mikami B, Hirose M, Sacchettini JC (1993) Bio-889 chemistry 32:11963–11968890 16. MacGillivray RT, Moore SA, Chen J, Anderson BF, Baker H,891 Luo Y, Bewley M, Smith CA, Murphy ME, Wang Y, Mason892 AB, Woodworth RC, Brayer GD, Baker EN (1998) Biochem-893 istry 37:7919–7928894 17. He QY, Mason AB, Tam BM, MacGillivray RT, Woodworth895 RC (1999) Biochemistry 38:9704–9711896 18. Byrne SL, Chasteen ND, Steere AN, Mason AB (2010) J Mol897 Biol 396:130–140
89819. Steere AN, Byrne SL, Chasteen ND, Smith VC, MacGillivray899RT, Mason AB (2010) J Biol Inorg Chem 15:1341–135290020. James NG, Byrne SL, Steere AN, Smith VC, MacGillivray RT,901Mason AB (2009) Biochemistry 48:2858–286790221. James NG, Berger CL, Byrne SL, Smith VC, MacGillivray RT,903Mason AB (2007) Biochemistry 46:10603–1061190422. Halbrooks PJ, Giannetti AM, Klein JS, Bjorkman PJ, Larouche905JR, Smith VC, MacGillivray RT, Everse SJ, Mason AB (2005)906Biochemistry 44:15451–1546090723. Nurizzo D, Baker HM, He QY, MacGillivray RT, Mason AB,908Woodworth RC, Baker EN (2001) Biochemistry 40:1616–162390924. He QY, Mason AB, Tam BM, MacGillivray RT, Woodworth910RC (1999) Biochem J 344:881–88791125. Byrne SL, Mason AB (2009) J Biol Inorg Chem 14:771–78191226. Spencer DS, Xu K, Logan TM, Zhou HX (2005) J Mol Biol913351:219–23291427. Hofmeister F (1888) Arch Exp Pathol Pharmakol 24:247–26091528. Baldwin RL (1996) Biophys J 71:2056–206391629. Perez-Jimenez R, Godoy-Ruiz R, Ibarra-Molero B, Sanchez-917Ruiz JM (2004) Biophys J 86:2414–242991830. Kumar R, Mauk AG (2009) J Phys Chem B 113:12400–1240991931. Cacace MG, Landau EM, Ramsden JJ (1997) Q Rev Biophys92030:241–27792132. Von Hippel PH, Wong KY (1964) Science 145:577–58092233. Pegram LM, Record MT Jr (2008) J Phys Chem B923112:9428–943692434. Record MT Jr, Anderson CF, Lohman TM (1978) Q Rev Bio-925phys 11:103–17892635. Villa A, Zecca L, Fusi P, Colombo S, Tedeschi G, Tortora P927(1993) Biochem J 295:827–83192836. Apetri AC, Surewicz WK (2003) J Biol Chem 278:22187–2219292937. Aasa R, Malmstrom BG, Saltman P, Vanngard T (1963) Bio-930chim Biophys Acta 75:203–22293138. Sun H, Li H, Sadler PJ (1999) Chem Rev 99:2817–284293239. MacGillivray RTA, Mason AB (2002) In: Transferrin Temple-933ton DM (ed). Marcel Dekker, Inc., New York93440. He QY, Mason AB (2002) In: Templeton DM (ed). Marcel935Dekker, Inc., New York93641. Guo M, Sun H, McArdle HJ, Gambling L, Sadler PJ (2000)937Biochemistry 39:10023–1003393842. Tinoco AD, Valentine AM (2005) J Am Chem Soc939127:11218–1121994043. Tinoco AD, Incarvito CD, Valentine AM (2007) J Am Chem941Soc 129:3444–345494244. Hemadi M, Ha-Duong NT, Plantevin S, Vidaud C, El Hage943Chahine JM (2010) J Biol Inorg Chem 15:497–50494445. Chikh Z, Ha-Duong NT, Miquel G, El Hage Chahine JM (2007)945J Biol Inorg Chem 12:90–10094646. Zhong W, Parkinson JA, Guo M, Sadler PJ (2002) J Biol Inorg947Chem 7:589–59994847. Dautry-Varsat A, Ciechanover A, Lodish HF (1983) Proc Natl949Acad Sci USA 80:2258–226295048. Baker EN (1994) Adv Inorg Chem 41:389–46395149. Mason AB, Woodworth RC (1984) J Biol Chem 259:1866–187395250. Mason AB, Brown SA, Church WR (1987) J Biol Chem953262:9011–901595451. Mason AB, Woodworth RC, Oliver RW, Green BN, Lin LN,955Brandts JF, Savage KJ, Tam BM, MacGillivray RT (1996)956Biochem J 319:361–36895752. Thibodeau SN, Lee DC, Palmiter RD (1978) J Biol Chem958253:3771–377495953. Anderson BF, Baker HM, Norris GE, Rice DW, Baker EN960(1989) J Mol Biol 209:711–73496154. Baker EN, Lindley PF (1992) J Inorg Biochem 47:147–16096255. Haridas M, Anderson BF, Baker EN (1995) Acta Crystallogr D963Biol Crystallogr 51:629–646
AQ4
J Biol Inorg Chem
123Journal : Large 775 Dispatch : 12-5-2014 Pages : 16
Article No. : 1145h LE h TYPESET
MS Code : JBIC-13-08-00139 h CP h DISK4 4
Au
tho
r P
ro
of
UNCORRECTEDPROOF
964 56. Anderson BF, Baker HM, Norris GE, Rumball SV, Baker EN965 (1990) Nature 344:784–787966 57. Kurokawa H, Mikami B, Hirose M (1995) J Mol Biol967 254:196–207968 58. Kurokawa H, Dewan JC, Mikami B, Sacchettini J, Hirose M969 (1999) J Biol Chem 274:28445–28452970 59. Jeffrey PD, Bewley MC, MacGillivray RT, Mason AB, Wood-971 worth RC, Baker EN (1998) Biochemistry 37:13978–13996972 60. Sharma AK, Rajashankar KR, Yadav MP, Singh TP (1999) Acta973 Crystallogr Sect D55:1152–1157974 61. Thorstensen K, Romslo I (1990) Biochem J 271:1–9975 62. Hemadi M, Ha-Duong NT, El HageChahine JM (2006) J Mol976 Biol 358:1125–1136977 63. Schlabach MR, Bates GW (1975) J Biol Chem 25:2182–2188978 64. Campbell RF, Chasteen ND (1977) J Biol Chem 252:5996–6001979 65. Zweier JL, Wooten JB, Cohen JS (1981) Biochemistry980 20:3505–3510981 66. Aisen P, Leibma A, Pinkowitz RA, Pollack S (1973) Bio-982 chemistry 12:3679–3684983 67. Aisen P, Brown EB (1975) Prog Hematol 9:25–56984 68. Folajtar DA, Chasteen ND (1982) J Am Chem Soc985 104:5775–5780986 69. Bell JD, Brown JD, Kubal G, Sadler PJ (1988) Bio Chem Soc987 Trans 16:714–715988 70. Grady JK, Mason AB, Woodworth RC, Chasteen ND (1995)989 Biochem J 309:403–410990 71. Harris WR, Cafferty AM, Abdollahi S, Trankler K (1998)991 Biochim Biophys Acta 1383:197–210992 72. He QY, Mason AB, Nguyen V, MacGillivray RT, Woodworth993 RC (2000) Biochem J 350:909–915994 73. Wishnia A, Weber I, Warner RC (1961) J Am Chem Soc995 83:2071–2080996 74. Byrne SL, Steere AN, Chasteen ND, Mason AB (2010) Bio-997 chemistry 49:4200–4207998 75. Egan TJ, Ross DC, Purves LR, Adams PA (1992) Inorg Chem999 31:1994–1998
1000 76. Marques HM, Watson DL, Egan TJ (1991) Inorg Chem1001 30:3758–37621002 77. Kretchmar SA, Raymond KN (1988) Inorg Chem 27:1436–14411003 78. Williams J, Chasteen ND, Moreton K (1982) Biochem J1004 201:527–5321005 79. Harris WR, Bali PK (1988) Inorg Chem 27:2687–26911006 80. Baldwin DA, Egan TJ, Marques HM (1990) Biochim Biophys1007 Acta 1038:1–9
100881. Egan TJ, Zak O, Aisen P (1993) Biochemistry 32:8162–8167100982. Marques HM, Walton T, Egan TJ (1995) J Inorg Biochem101057:11–21101183. Zak O, Tam B, MacGillivray RT, Aisen P (1997) Biochemistry101236:11036–11043101384. Li Y, Harris WR (1998) Biochim Biophys Acta 1387:89–102101485. Marques HM, Egan TJ, Pattrick G (1990) S Afr J Sci 86:21–24101586. Muralidhara BK, Hirose M (2000) J Biol Chem1016275:12463–12469101787. Mizutani K, Muralidhara BK, Yamashita H, Tabata S, Mikami1018B, Hirose M (2001) J Biol Chem 276:35940–35946101988. Hamilton DH, Turcot I, Stintzi A, Raymond KN (2004) J Biol1020Inorg Chem 9:936–944102189. Mazurier J, Spik G (1980) Biochim Biophys Acta 629:399–408102290. Harris WR (1986) J Inorg Biochem 27:41–52102391. Kojima N, Bates GW (1979) J Biol Chem 254:8847–8854102492. Nakazato K, Yamamura T, Satake K (1988) J Biochem1025103:823–828102693. Bali PK, Harris WR (1990) Arch Biochem Biophys1027281:251–256102894. Turcot I, Stintzi A, Xu J, Raymond KN (2000) J Biol Inorg1029Chem 5:634–641103095. Hissen AHT, Moore MM (2005) J Biol Inorg Chem 10:211–220103196. Baldwin DA, de Sousa DM (1981) Biochem Biophys Res1032Commun 99:1101–1107103397. Lehrer SS (1969) J Biol Chem 244:3613–3617103498. Bali PK, Harris WR (1989) J Am Chem Soc 111:4457–4461103599. Halbrooks PJ, Mason AB, Adams TE, Briggs SK, Everse SJ1036(2004) J Mol Biol 339:217–2261037100. Zhang M, Gumerov DR, Kaltashov IA, Mason AB (2004) J Am1038Soc Mass Spectrom 15:1658–16641039101. Santoro MM, Bolen DW (1988) Biochemistry 27:8063–80681040102. Tanford C (1968) Adv Protein Chem 23:121–2821041103. Curtis RA, Lue L (2006) Chem Eng Sci 61:907–9231042104. Ramos CHI, Baldwin RL (2002) Protein Sci 11:1771–17781043105. Zhang Y, Cremer PS (2006) Curr Opin Chem Biol 10:658–6631044106. Timasheff SN (1993) Annu Rev Biophys Biomol Struct104522:67–971046107. Nishimura C, Uversky VN, Fink AL (2001) Biochemistry104740:2113–21281048108. van Asselt EJ, Dijkstra BW (1999) FEBS Lett 458:429–4351049109. Harris WR (2012) Biochim Biophys Acta 1820:348–361
J Biol Inorg Chem
123Journal : Large 775 Dispatch : 12-5-2014 Pages : 16
Article No. : 1145h LE h TYPESET
MS Code : JBIC-13-08-00139 h CP h DISK4 4
Au
tho
r P
ro
of
Journal : 775
Article : 1145 123the language of science
Author Query Form
Please ensure you fill out your response to the queries raised below and return this form along
with your corrections
Dear Author
During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully
against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the ‘Author’s
response’ area provided below
Query Details Required Author’s Response
AQ1 Please check and confirm the edit in the following sentence: The contribution of electrostatic interactionsto the stability of ovotransferrin-Fe3? (oTf-Fe3?) complex has been assessed by equilibriumexperiments that measure iron retention level of diferric-ovotransferrin (Fe2oTf) as a function of pHand urea in the presence of salts (NaCl, Na2SO4, NaBr, NaNO3) and sucrose at 25 �C
AQ2 Please confirm if both terms "urea-induced denaturation", and "urea denaturation-induced’ signifydifferent processes
AQ3 Please check and confirm the edit in the following sentence: This finding further confirms that the Fe2oTfresponds to increased urea concentration by means of a coupled process in which the urea-induced ironrelease reaction occurs prior to the unfolding reaction
AQ4 Please check and confirm the edit in the following sentence: However, at pH 5.6, the salt-inducedacceleration of Fe2? and Fe3? release is particularly pronounced at low salt concentrations but issaturated at *0.2(±0.05) M Na2SO4 or *0.4(±0.1) M NaNO3/NaCl, which suggests that theCoulombic interactions play crucial role in the accelerating the iron release from FeNoTf underendosomal pH conditions